State-of-the-art in vivo imaging solutions, offering a comprehensive range of modalities:

• Magnetic Resonance Imaging (MRI) – High-resolution anatomical and functional imaging for brain, tumor, and organ studies.
• In Vivo Optical Imaging – Monitoring cellular and molecular events with bioluminescence or fluorescence imaging.
• Positron Emission Tomograph (PET-CT) – Quantitative, high-sensitivity imaging for metabolic and tracer-based studies.
• Single Photon Emission Computed Tomography (SPECT-CT) – High-resolution functional and anatomical data to support drug development.
• DEXA (Dual-Energy X-ray Absorptiometry) – Bone mineral density (BMD), body composition, and lean/fat mass distribution in small animals.
• Short-Wave Infrared (SWIR) Imaging – Deep tissue penetration and enhanced contrast for real-time drug biodistribution.
• Wide Field Calcium Imaging – Functional connectivity studies and imaging cortex-wide neuronal signaling with genetically encoded calcium indicators.
• Confocal Microscopy Imaging – High-resolution optical sectioning for detailed visualization of cells and tissues.
• Super-resolution Imaging – Nanometer-scale imaging that surpasses the diffraction limit for ultra-fine structural detail.
• Live Cell Imaging – Time-lapse microscopy capturing dynamic cellular processes in real time under physiological conditions.
• Intravital and Deep Tissue Imaging – Imaging within living organisms to visualize cellular interactions in intact, deep biological tissues.

Our spatial biology pipelines are fully integrated into H&E and IHC detections and include:

• Full-Service Spatial Transcriptomics using the Xenium In Situ instrument for single-cell gene expression mapping within intact tissue.
• Comprehensive Tissue Microarray (TMA) construction services enabling efficient and standardized analysis of large tissue cohorts.
• Fresh and FFPE Tissue Single-Cell RNAseq (scRNAseq) offering high-quality single-cell RNA sequencing with specialized workflows optimized for FFPE tissue interpretation.

analytical services to support
drug discovery, contrast agent development, and biomolecular research.
Using advanced NMR, HPLC, and LC-MS technologies, we provide precise characterization, quantification, and quality control of
small molecules, contrast agents, and biologics.

• LC-MS and MS – drug quantification, purity analysis, metabolic profiling, DMPK, and structural elucidation.
• NMR spectroscopy (¹H, ¹³C, 2D NMR, and more) – for structural determination, impurity profiling, confirming metabolic pathways, and confirmation of compound identity.
• HPLC Services – small-molecule characterization, impurity analysis, stability studies, and method optimization, providing detailed chromatographic data and expert interpretation.

• Study scoping & hypothesis refinement:
  Clarifying scientific questions, defining primary and secondary endpoints, and aligning study design with your specific therapeutic, imaging, or biomarker objectives.
• Model selection & cohort definition:
  Recommending appropriate in vitro and in vivo models (oncology, neurology, inflammation, infectious disease, etc.), defining inclusion/exclusion criteria, and determining control, treatment, and reference arms.
• Dosing strategy & sampling schedule:
  Designing routes of administration, dose levels, escalation schemes, and time points for imaging, biofluid sampling, and tissue collection to capture relevant PK/PD and efficacy dynamics.
• Imaging & analytical endpoint integration:
  Coordinating in vivo imaging (MRI, PET/SPECT, CT, optical, SWIR, DEXA) with analytical readouts (LC-MS/MS, NMR, HPLC, proteomics, metabolomics) to generate harmonized, quantitative datasets from each animal or sample.
• Randomization, blinding & bias control:
  Implementing robust randomization schemes, blinding strategies, and pre-specified analysis plans to minimize bias and improve reproducibility across experimental runs.
• Power & statistical planning:
  Estimating sample sizes, variance, and effect sizes, and recommending appropriate statistical tests to ensure that the study is adequately powered while making efficient use of resources.
• Data structure & analysis-ready outputs:
  Defining how imaging, histology, flow cytometry, omics, and bioanalytical data will be captured, annotated, and organized to streamline downstream quantification, visualization, and bioinformatics.
• Documentation, SOPs & reporting framework:
  Preparing protocol documents, workflow diagrams, and report templates that support internal decision-making and can be adapted for regulatory or partner-facing documentation.